Drugs / HG205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06025032 | Mar 2023 → Apr 2025 | hearing loss disorder | HuidaGene Therapeutics Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HG205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06025032 ↗ |
| Modality | CRISPR / gene editing | “HG205 as CRISPR/Cas13 RNA base-editing therapy” NCT06025032 ↗ |
| Route | Other | “Unilateral intracochlear injection/subject” NCT06025032 ↗ |